Nivolumab and AVD for Early-Stage Unfavorable Hodgkin Lymphoma (NIVAHL)
Paul Jan Bröckelmann1, Helen Goergen2, Ulrich Keller3, et al.
1 German Hodgkin Study Group (GHSG) and Department I of Internal Medicine, Center for Inte-grated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), University of Cologne, Koeln, Germany
2 German Hodgkin Study Group (GHSG) and Department I of Internal Medicine, Center for Inte-grated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), University of Cologne, Co-logne, Germany
3 Klinikum Rechts der Isar der TU München, Munich, Germany
Program: Oral and Poster Abstracts Type: Oral Session: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma – Clinical Studies: Immunotherapy Approaches in Hodgkin Lymphoma Hematology Disease Topics & Pathways: Adult, Therapy Sequence, Biological, Diseases, Drug-drug Interaction, Non-Biological, Therapies, Combinations, Hodgkin Lymphoma, Chemotherapy, Checkpoint Inhibitors, Study Population, Clinically Relevant, Lymphoid Malignancies Saturday, December 7,…
